Stability-Indicating HPLC Method for the Simultaneous Determination of HIV Tablet Containing Emtricitabine, Tenofovir Disoproxil Fumarate, and Rilpivirine Hydrochloride in Pharmaceutical Dosage Forms

Table 3

Evaluation data of robustness study.

Parameter	Sampling interval	EMT			TDF			RPV
		Amount present; (mg)	(%)	%RSD	Amount present; (mg)	(%)	%RSD	Amount present; (mg)	(%)	%RSD
Wavelength	−1 nm	200.25	100.12	0.334	297.04	99.01	0.837	24.63	98.54	0.001
	+1 nm	200.10	100.50	0.624	299.47	99.82	0.323	24.92	99.68	0.029
Mobile phase	−2%	200.16	100.08	0.225	299.44	99.81	0.163	24.82	99.30	0.689
	+2%	200.09	100.04	0.430	298.92	99.64	0.509	24.68	98.75	0.370
Flow rate	−0.1 mL	198.81	99.40	0.837	300.55	100.18	0.019	24.47	97.89	1.469
	+0.1 mL	196.28	98.14	3.192	298.49	99.49	0.403	24.68	98.74	0.378
pH	−0.05	199.7	99.85	0.74	298.7	99.56	0.21	24.59	98.36	0.22
	+0.05	199.9	99.95	0.63	300.4	100.1	0.11	24.71	98.84	0.34